Rosanna Tarricone

Government, Health and Not for Profit

rosanna.tarricone@unibocconi.it

Download v-card

PDF

Curriculum Vitae

Rosanna Tarricone is Associate Dean at SDA Bocconi School of Management and Associate Professor in Public Administration at Bocconi University, Department of Social and Political Science, Milan. She graduated in Business Administration at Bocconi University and holds an MSc in Health Services Management and PhD in Public Health and Policy, both from the London School of Hygiene and Tropical Medicine, University of London, UK. She has over 100 publications in the areas of health policy, healthcare management, economic analysis of health care services and health technology assessment (HTA).

In the last 10 years Rosanna has been awarded over 10 multi-annual competitive research grants from international institutions such as the European Union, the Swiss Bridge Award and InHealth (USA). She has been the leader of MedtecHTA, a large, three-year EU-funded research project that has made recommendations on how to improve methods for assessing the effectiveness and cost-effectiveness of medical devices and she currently serves as scientific supervisor of COMED, a three-year EU-funded research project on improving assessment methods of costs and outcomes analysis of medical technologies, including mhealth.

Rosanna serves as an expert for the DG Research and DG Health of the European Commission. She facilitates the continuous exchange of experiences and harmonisation of methods and procedures between the HTA Agencies of the EU Member States within EUnetHTA. Since 2007 Rosanna is an advisor for the Ministry of Health (MoH) of Italy and has contributed to the design and development of the National Programme of HTA for Medical Devices. She is part of the Experts Panel aimed at advising the MoH on the future of the Italian NHS.

Between 2005 and 2010 Rosanna held the position of Director Economic Affairs at Medtech Europe and contributed to develop research and generate robust evidence around medical devices by launching the European Health Technology Institute for Socio-Economic Research, a partnership between European universities (Bocconi University, London School of Economics and Technische Universität Berlin) and policymakers (European Commission, WHO).

Rosanna is an active member of ISPOR. She served on the ISPOR Board of Directors from 2016-2018, and currently chairs the Publications Management Advisory Board (MAB). She is Co-Chair of 2019’s North America Conference in New Orleans.

Publications

Books

Tarricone (a cura di). Politiche per la salute e scelte aziendali. Impatto sull’innovazione e diffusione delle tecnologie mediche. EGEA, 2012
Tarricone. Innovazione e competitività dei sistemi industriali regolati. le imprese dei dispositivi medici. EGEA, 2010.
Tarricone, A. Tsouros. Homecare in Europe. World Health Organisation, 2008.
Tarricone R., Valutazioni economiche e management in sanità. Applicazioni ai programmi e tecnologie sanitarie, Milano, McGraw-Hill, 2004.

Articles

Ciani, O; Cucciniello, M; Petracca, F; Nicod, E; Tarricone, R et al. The Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer. BMJ Open 2019; 9: e025483
Rognoni, C; Tarricone, R; Brusaferro, S; Mazzacane, S et al. Impact of a probiotic-based hospital sanitation on antimicrobial resistance and HAI-associated antimicrobial consumption and costs: a multicenter study. Infection and Drug Resistance 2019; 12: 501-510
Meregaglia M, Borsoi L, Cairns J, Tarricone R. Mapping health-related quality of life scores from FACT-G, FAACT and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer-cachexia. European Journal of Health Economics 2019; 20(2)181-193
Armeni P, Boscolo PR, Callea G, Cavallo MC, Ciani O, Costa F, Ghislandi S, Tarricone R, Torbica A. Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci. In Rapporto OASI 2018, Egea, Milano, pp. 567-586
Ciani O, Federici C, Furnari A, Tarricone R. Gli esiti di salute del Servizio Sanitario Nazionale. In Rapporto OASI 2018, Egea, Milano, pp. 277-317
Drummond M, Tarricone R, Torbica A. Economic Evaluation of Medical Devices. In J Hamilton, A Dixit, S Edwards, and K Judd (eds), Oxford Research Encyclopedia of Economics and Finance, Oxford University Press, 2018
Drummond M, Tarricone R. Public Versus Private Financing. In P. Adinolfi e E Borgonovi (eds), The myths of health care: towards new models of leadership and management in the healthcare sector, Springer 2018, pp. 134-137
Armeni P, Torbica A, Tarricone R, Drummond M. Diffusion without Evidence: A Study on High-Risk Medical Devices. Value in Health 2018; 21(s1): S175
Rognoni C; Tarricone R et al. Budget impact analysis of a biosynthetic mesh for incisional hernia repair. Clinical Therapeutics 2018; 40(11): 1830-1844
Pallari E, Lewison G, Ciani O, Tarricone R, Sommariva S. Begum M, Sullivan R. The impacts of diabetes research from 31 European Countries in 2002 to 2013, Research Evaluation 2018; 27(3): 270-282.
Federici, C; Perego, F; Borsoi, L; Tarricone, R et al. Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients. BMJ Open 2018;8:e022291
Tarricone R et al per il SAN-ICA Study Group. Reducing healthcare-associated infections incidence by a probiotic-based sanitation system: A multicentre, prospective, intervention study. PLoS ONE 2018; 13(7): e0199616.
Rognoni, C; Ciani, O; Sommariva, S; Tarricone, R (et al) Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis BMC Cancer 2018; 18: 745
Torbica A, Tarricone R, Drummond M. Does the approach to economic evaluation in health care depend on culture, values and institutional context? European Journal of Health Economics 2018; 19(6): 769-774
Rognoni C, Ciani O, Sommariva S, Tarricone R. Cost-effectiveness analysis of treatments involving radioembolization in intermediate stage hepatocellular carcinoma. Journal of Comparative Effectiveness Research 2018;7(3):209-221.
Tarricone R, Armeni P, Amatucci F, Borsoi L, Callea G, Costa F, Federici C, Torbica A, Marletta M. Programma Nazionale HTA per dispositivi medici: prove tecniche di implementazione. In Rapporto OASI 2017, Egea, Milano, pp. 535-553
Boscolo PR, Ciani O, Federici C, Furnari A, Tarricone R. Gli esiti di salute del Servizio Sanitario Nazionale. In Rapporto OASI 2017, Egea, Milano, pp. 217-317
Berger ML, Sox H, Willke RJ, Brixner DL, Eichler H-G, Goettsch W, Madigan D, Makady A, Schneeweiss S, Tarricone R, Wang SV, Watkins J, Mullins CD. Good Practices for Real‐World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐World Evidence in Health Care Decision Making. Value in Health 2017;20:1003-1008.
Begum M, Lewison G, Sommariva S, Ciani O, Tarricone R, and Sullivan R. European Diabetes Research And Its Funding, 2002-13. Diabetic Medicine 2017 Oct;34(10):1354-1360.
Mujica-Mota R, Watson LK, Tarricone R, Jäger M. Cost-Effectiveness of Timely Versus Delayed Primary Total Hip Replacement In Germany: A Social Health Insurance Perspective. Orthopedic Reviews 2017;9(3):7161. doi: 10.4081/or.2017.7161.
Callea G, Cavallo MC, Tarricone R, Torbica A. Learning effect and diffusion of innovative medical devices: the case of transcatheter aortic valve implantation in Italy. Journal of Comparative Effectiveness Research 2017; 6(4): 279-292
Rognoni C, Tarricone R. Intermittent catheterisation with hydrophilic and non-hydrophilic urinary catheters: systematic literature review and meta-analyses. BMC Urology 2017;17(4):1-11.
Callea A, Armeni P, Marsilio M, Jommi C, Tarricone R. The impact of HTA and procurement practices on the selection and prices of medical devices. Social Science and Medicine 2017; 174:89-95.
Tarricone R, Torbica A, Drummond M. Challenges in the Assessment of Medical Devices: the MedtecHTA project. Health Economics 2017;26(Suppl S1):5-12.
Tarricone R, Callea G, Ogorevc M, Prevolnik Rupel V. Improving the methods for the economic evaluation of medical devices. Health Economics 2017;26(Suppl S1):70-92
Rothery C, Claxton K, Palmera S, Epstein D, Tarricone R, Sculpher M. Characterising uncertainty in the assessment of medical devices and determining future research needs. Health Economics 2017;26(Suppl S1):109-123.
Tarricone R, Torbica A, Drummond M. (for the MedtecHTA project group) Key Recommendations from the MedtecHTA Project. Health Economics 2017;26(Suppl S1):145-152.
Rognoni C and Tarricone R. Healthcare Resource Consumption for Intermittent Catheterization: Cost-Effectiveness of Hydrophilic Catheters and Budget Impact Analyses. BMJ Open 2017; 7(1):e012360
Rognoni C, Sommariva S, Ciani O, Tarricone R. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Value in Health 2017; 20(3): 336-344
Drummond M, Tarricone R, Torbica A, “Incentivising research into the effectiveness of medical devices” European Journal of Health Economics 2016; 17:1055-1058.
Caselli E, Berloco F, Tognon L, Villone G, La Fauci V, Nola S, Antonioli P, Coccagna M, Balboni PG, Pelissero G, Tarricone R, Trua N, Brusaferro S, Mazzacane S, and Study Group SAN-ICA. Influence of sanitizing methods on healthcare-associated infections onset: a multicentre, randomized, controlled pre-post interventional study. Journal of Clinical Trials, 2016; 6: 285.
Ciani O, Tarricone R, Torbica A. Programma nazionale HTA per dispositivi medici: quali sfide per l’implementazione? In Rapporto OASI 2016, Egea, Milano pp. 615-634
Rognoni C, Ciani O, Sommariva S, Facciorusso A, Tarricone R, Bhoori S, Mazzaferro V, “Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses” Oncotarget 2016; 7(44): 72343-72355
Tarricone R, Boscolo P.R, Armeni P. What type of clinical evidence is needed to assess health technologies? European Respiratory Review, 2016; 25: 259-265
Ciani O, Tarricone R, Taylor RS. Comparing drug and non-drug technologies in comparative effectiveness research. In Comparative effectiveness research in health services, eds A Levy and B Sobolev, Springer 2016
Ciani O, Arendsen E, Romancik M, Lunik R, Costantini E, Di Biase M, Morgia G, Fragalà E, Roman T, Bernat M, Guazzoni G, Tarricone R, Lazzeri M. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulphate (CS) for the treatment of female recurrent urinary tract infections: a European multicenter nested case-control study. BMJ Open 2016;6: e009669.
Armeni P, Boscolo PR, Tarricone R, Capodanno D, Maggioni A, Grasso C, Maisano F. Real-World Cost Effectiveness of Mitraclip combined with Medical Therapy Versus Medical Therapy Alone in Patients With Moderate or Severe Mitral Regurgitation. International Journal of Cardiology 2016; 209:153-160.
Rognoni C, Venturini S, Meregaglia M, Marmifero M, Tarricone R, “Efficacy and safety of iron supplementation in anaemic patients: a systematic review and meta-analysis of randomized controlled trials”. Clinical Drug Investigations 2016; 36(3):177-194
Tarricone R, Medina Lara A, Abu Koush D. A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life. Critical Reviews in Oncology/Hematology 2016; 99:37-48.
Tarricone R, Ricca G, Nyanzi-Wakholi B, Medina Lara A. Impact of cancer anorexia-Cachexia Syndrome on Health-Related Quality of Life and Resource Utilisation: a Systematic Review. Critical Reviews in Oncology/Hematology 2016; 99:49-62.
Sommariva S, Pongiglione B, Tarricone R. Impact of Chemotherapy- Induced Nausea and Vomiting on Health-Related Quality of Life and Resource Utilization: a Systematic Review. Critical Reviews in Oncology/Hematology 2016;99:13-36.
Valzania C, Torbica A, Tarricone R, Leyva F, Boriani G. Implant rates of cardiac implantable electrical devices in Europe: a systematic literature review. Health Policy 2016;120(1):1-15.
Ciani O, Armeni P, Boscolo PR, Cavazza M, Jommi C, Tarricone R. De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making. Health Policy & Technology 2015;5(1):47-64.
Generali D, Venturini S, Rognoni C, Ciani R, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R. A Network Meta-Analysis of Everolimus plus Exemestane versus Chemotherapy in the First and Second Line Treatment of Estrogen Receptor Positive Metastatic Breast Cancer. Breast Cancer Research and Treatment 2015;152(1):95-117.
Gonzales FM, Finch AP, Armeni P, Boscolo PR, Tarricone R. Comparative Effectiveness of Mitraclip versus Optimal Medical Therapy in High-Risk Surgical Patients: a Comprehensive Review. Expert Review of Medical Devices 2015;12(4): 471-485.
Gehring M, Jommi C, Tarricone R, Cirenei M, Ambrosio G. Towards a More Competitive Italy in Clinical Research: The Survey of Attitudes towards Trial sites in Europe (The SAT-EU StudyTM). Epidemiology, Biostatistics and Public Health 2015;12(1):1-9
Beresniak A, Medina-Lara A, Auraye JP, Weverf A, Praetf JC, Tarricone R, Torbica A, Dupont D, Lamure M, Durue G. Validation of the underlining assumptions of the QALY outcome: results from the ECHOUTCOME European project. Pharmacoeconomics 2015;33(1):61-69
Gehring M, Jommi C, Tarricone R, Cirenei M, Ambrosio G. Towards a More Competitive Italy in Clinical Research: The Survey of Attitudes towards Trial sites in Europe (The SAT-EU StudyTM). Epidemiology, Biostatistics and Public Health 2014. Published online 2015;12:1
Sommariva S, Tarricone R, Lazzeri M, Ricciardi W, Montorsi F. Prognostic value of CCP score in patients with prostate cancer: a systematic review and meta-analysis. European Urology (accepted on 2014, November 19th)
Tarricone R, Torbica A, Ferrè F, Drummond M. Generating Appropriate Clinical Data for Value Assessment of Medical Devices: What Role Does Regulation Play? Expert Review of Pharmacoeconomics and Outcome Research 2014;14(5):707-718.
Compagni, A. Melegaro, R. Tarricone. Systematic review of the economic literature on genetic testing for the prevention of venous thromboembolism. Italian Journal of Public Health 2012;9:s36-s45.
Tarricone, A. Torbica. Costing and performance in healthcare management. Faltin, F.W, Kenett, R.S., Ruggeri, F. (a cura di) Statistical methods in healthcare. Wiley, UK, 2012, pp.386-404.
Callea, R. Tarricone, A. Medina Lara. Economic evidence of interventions for acute myocardial infarction: a review of the literature. EUROINTERVENTION 2012;8:P71-P76.
Mujica-Mota, R. Tarricone, O. Ciani, J.F.P. Bridges, M. Drummond. Determinants of demand for total hip and and knee arthroplasty: a systematic literature review. BMC Health Services Research 2012;12:225-257.
Ciani, R. Tarricone, A. Torbica. Diffusion and use of Health Technology Assessment in policy making: what lessons for decentralised healthcare systems? Health Policy, 2012.
Tarricone. Setting the Scene: The Challenges of Universal Health Coverage and the Contribution of Management Education. Value in Health, 2012.
Drummond, R. Tarricone, A. Torbica. Assessing the added value of health technologies: reconciling different perspectives. Value in Health, 2012.
Tarricone, G. Valotti. Il miglioramento del performance management nelle aziende sanitarie pubbliche: oltre le mode e le tradizioni. Autori Vari (a cura di) Strategia e performance management nelle aziende sanitarie pubbliche. EGEA, 2012, pp.107-110.
Armeni, O. Ciani, V.A. Vella, M.C. Cavallo, R. Tarricone. I Dispositivi medici in Italia: un settore, tanti mercati. MECOSAN 2012:65-81.
Compagni, A. Melegaro, R. Tarricone. Systematic review of the economic literature on genetic testing for the prevention of venous thromboembolism. Italian Journal of Public Health 2012;9:s36-s45.
Tarricone, M. Drummond. Challenges in the clinical and economic evaluation of medical devices: the case of transcathether aortic valve implantation. Journal of Medical Marketing 2012;11:221-229.
Armeni, O. Ciani, R. Tarricone, I. Palla, F. Pierotti, G. Turchetti. PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani. MECOSAN 2011;79:9-22.
Tarricone. Pharmaco-economics and decision making in health care. The case of “extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis”. Internal and Emergency Medicine 2011;6:581-582.
C Sorenson, R Tarricone, M Siebert, M Drummond. Applying Health Economics for Policy Decision Making: Do Devices Differ From Drugs?. EUROPACE 2011;13:ii54-ii58.
Tarricone. Innovazione e competitività dei sistemi industriali regolati. le imprese dei dispositivi medici. EGEA, 2010.
MC Cavallo, O Ciani, A Gugiatti, C Jommi, R Tarricone. La gestione dell'innovazione tecnologica in sanità. Analisi e confronto di alcune politiche regionali in Italia. MECOSAN 2010;74:37-65.
Tarricone, A. Torbica, F. Franzetti, V.D. Rosenthal. Hospital cost of central line-associated bloodstream infections and cost-effectiveness of closed vs. open infusion containers. The case of Intensive Care Units in Italy. Cost Effectiveness and Resource Allocation 2012;8:1-10.
Aguzzi G, Bartoli S, Tarricone R. Systematic review of urinary incontinence and overactive bladder cost-of-illness studies. The Open Pharmacoeconomics & Health Economics Journal 2010;2:11-24.
Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. UROLOGY 2010;75:491-500.
Tarricone, C. Giaquinto, N. Largeron, M. Trichard. Analisi economica dei costi e dei benefici dell’implementazione di un programma di prevenzione antirotavirus con il vaccino pentavalente in Italia. Pharmacoeconomics Italian Research Articles 2009; 11(1): 1-13.
Torbica, R. Tarricone, S. Calciolari, V. Branca, SM Gaini. Analisi dei costi del trattamento dell’aneurisma intracranico in Italia. Pharmacoeconomics Italian Research Articles 2009; 11(1): 25-37.
Drummond, A. Griffin, R. Tarricone. Economic evaluation for devices and drugs. Same or different? Value in Health 2009; 12(4):402-404.
Fattore, MC Cavallo, R. Tarricone. Lo sviluppo dell’Health Technology in Italia: contenuti, approcci e riferimenti internazionali. In Rapporto OASI 2008. L’aziendalizzazione della sanità in Italia. EGEA, 2008.
Tarricone, G. Aguzzi, A. Capone, et al. How complicated skin and soft tissue infections are treated in Italy: economic evaluation of inpatient intravenous antibiotic treatment in seven hospitals. Journal of Medical Economics 2008; 11:265-279.
Tarricone, G. Aguzzi, F. Musì, L. Fariselli, A. Casasco. Cost-effectiveness for trigeminal neuralgia: Cyberknife vs microvascular decompression. Neuropsychiatric Disease and Treatment 2008; 4(3):647-652
Roggero P, Tarricone R, Mangiaterra V, et al. What do people think about disabled youth and employment in developing and developed countries? Results from an e-discussion hosted by the World Bank. Disability and Society 2006;21(6):645-650
Tarricone R. COI analysis: what room in health economics? Health Policy 2006;77(1):51-63
Tarricone R, Girolami F. Economic evaluation of a new antiemetic drug: palonosetron vs ondansetron. Clinical Drug Investigation 2005; 25(9):597-608.
Gerzeli S, Tarricone R, Zolo P, et al. The economic burden of stroke in Italy. The EcLIPSE Study: Economic Longitudinal Incidence-based Project for Stroke Evaluation. Neurological Science 2005; 26(2):72-80.
Otto M., Fricke F.U.,Tarricone R., "Analisi costi-efficacia della cura del dolore in Italia: la radioisotopoterapia con Samario-153 e la terapia convenzionale", Mecosan, 2004, n. 52: 41-50.
Heller B, Tarricone R. Oxaprozin versus diclofenac in NSAID-refractory periarthritis pain of the shoulder. Current Medical Research and Opinion 2004;20(8):1279-1290.
Tarricone R., "L'analisi di costo sociale. Quale ruolo per il management e l'economia sanitaria?", Mecosan, 2004, n. 50: 49-68.
Gillette JA, Tarricone R. Economic Evaluation of osteoarthritis treatment in Europe. Expert Opinion 2003; 4(3):327-341.
Tarricone R., Martelli E., Parazzini F., Darbà J., Le Pen C., Rovira J., "Economic Evaluation of Nimesulide Versus Diclofenac in the Treatment of Osteoarthritis in France, Italy and Spain". Clinical Drug Investigation 2001;21(7): 453-464.
Tarricone R., "Valutazione di convenienza economica comparata tra quetiapina e risperidone nel trattamento della schizofrenia", Pharmacoeconomics Italian research Articles, 2001, n. 3(1): 27-36.
Fattore G., Gerzeli S., Tarricone R., "The costs of farmacological treatment for major depression. The Italian prospective multi-centre observational incidence-based study", Pharmacoeconomics, 2000, n. 2: 167-174.
Tarricone R, Gerzeli S, Montanelli R, Frattura L, Percudani M, Racagni G. Direct and indirect costs of Schizophrenia in community psychiatric services in Italy. The GISIES study. Health Policy 2000; 51:1-18.
Colangelo I., Gerzeli S.,Tarricone R., "I costi ospedalieri dell’ictus in Italia: un confronto tra diversi modelli di cura", Mecosan, 2000, n. 38: 27-36.
Busca MR, Negrini C, Cuccurullo C, Tarricone R, Gerzeli S, Gandolfo C, Zolo P. Terapia dell’ictus: valutazione economica e modelli organizzativi. Argomenti di Neurologia 2000;10(2):75-79.
Inglese L, Graziani L, Tarricone R. Il trattamento percutaneo delle arteriopatie ostruttive periferiche: i perché di una scelta. Ital Heart J Suppl 2000; 1(9):1138-1147.
Tabacchi M.,Tarricone R., "Il programma regionale di sviluppo: il caso della Lombardia", Mecosan, 1998, n. 25: 53-62.
Tarricone R., Tabacchi M., "Un'analisi di convenienza economica comparata: il trattamento dell'osteoartrosi e dell'artrite reumatoide con Farmaci Antiinfiammatori Non-Steroidei", Mecosan, 1998, n. 25: 53-62 .
Montanelli R.,Tarricone R., "Il costo sociale della schizofrenia. Una rassegna ragionata della bibliografia", Mecosan, 1997, n. 21: 21-31.
Tarricone R., "Metodologia di indagine e primi risultati sul costo sociale della depressione maggiore in Italia (GISIED)", Mecosan, 1997, n. 22: 57-68.
Tarricone R., Fattore G., Percudani M., Recchia M., Serra G., Taddei C., "I costi dell'assistenza ospedaliera nella depressione maggiore: risultati di uno studio osservazionale multicentrico", Rivista di Psichiatria, 1997, n. 32 (5): 189-197 .
Tarricone R., Mantovani L., Montanelli R., "Valutazione economica dell'uso di Gas Plasma di perossido di idrogeno nella sterilizzazione in ambito ospedaliero", Mecosan, 1997, n. 20: 34-45 .
Cavallo C, Tarricone R. La valutazione del costo sociale delle malattie. Mecosan, 1996; 17: 8-16.
Tarricone R, Bertolini F, Grazioli I, Saggioro A. Valutazione economica della prevenzione con Misoprostol della gastropatia da farmaci anti-infiammatori non steroidei in Italia. Argomenti di Gastroenterologia Clinica, 1994; 7 (7): 263-269.
Tarricone R. Valutare il costo di una malattia. Prospettive Sociali e Sanitarie 1994; 19: 1-6.
Tarricone R., "Il sistema assicurativo sanitario olandese", Mecosan, 1994, n. 10: 98-110 .
Fattore G, Meneguzzo M, Tarricone R. Proposta di finanziamento del programma Medicare dell'Oregon. Mecosan, 1993; 5: 105-117.
Borgonovi E., Tarricone R., "Stima dei costi sanitari dell'ischemia critica cronica degli arti", Annali Italiani di Medicina Interna, 1993, n. 8 (suppl): 81-84 .
Tarricone R, Aspetti critici del sistema di riordino del Servizio Sanitario Nazionale. Mecosan, 1992; 3: 150-151.